|1.||Yan, Li: 9 articles (02/2015 - 04/2011)|
|2.||Kim, J Julie: 6 articles (05/2014 - 01/2012)|
|3.||Tolcher, Anthony W: 4 articles (02/2015 - 12/2011)|
|4.||Patnaik, Amita: 4 articles (02/2015 - 12/2011)|
|5.||de Bono, Johann S: 4 articles (02/2015 - 12/2011)|
|6.||Lu, Zhenxiao: 4 articles (04/2014 - 01/2012)|
|7.||Gandara, David R: 3 articles (10/2015 - 02/2015)|
|8.||Yap, Timothy A: 3 articles (02/2015 - 12/2011)|
|9.||Tetteh, Ernestina: 3 articles (02/2015 - 01/2014)|
|10.||Olmos, David: 3 articles (02/2015 - 12/2011)|
01/01/2014 - "MK-2206 treatment generated a significant reduction in tumor growth in vivo and promoted cell death through two mechanisms. "
11/01/2013 - "As activation of AKT might limit the RAD001-mediated anti-tumor effect, the efficacy of combined mTOR and AKT inhibition was investigated using the allosteric AKT inhibitor MK-2206. "
08/01/2015 - "Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors."
06/01/2015 - "We conducted a biomarker-driven trial of the combination of MK-2206, an allosteric AKT 1/2/3 inhibitor, and selumetinib, a MEK 1/2 inhibitor, in patients with CRC to evaluate inhibition of phosphorylated ERK (pERK) and AKT (pAKT) in paired tumor biopsies. "
02/15/2015 - "We conducted a dose/schedule-finding study evaluating MK-2206 and selumetinib in patients with advanced treatment-refractory solid tumors. "
06/01/2011 - "Furthermore, inhibition of eEF-2 kinase can reinforce the efficacy of a novel Akt inhibitor, MK-2206, against human glioma. "
01/01/2012 - "On the basis of the synergistic effect of MK-2206 on gefitinib observed in this study, the combination of these two drugs may be utilized as a new therapeutic regimen for malignant glioma."
02/08/2013 - "Here, we assessed the therapeutic possibility of inhibiting Notch and Akt in gliomas using the clinically available, selective small molecule inhibitors MRK003 and MK-2206. "
01/01/2012 - "In the presence of MK-2206, there was a significant increase in apoptosis in glioma cells treated with gefitinib. "
01/01/2012 - "We found that cotreatment with gefitinib and MK-2206 increased the cytotoxicity of this growth factor receptor inhibitor in the glioma cells, and the CompuSyn synergism/antagonism analysis showed that MK-2206 acted synergistically with gefitinib. "
|3.||Stomach Neoplasms (Stomach Cancer)
10/01/2013 - "In this study we evaluated the synergistic potential of MK-2206, an oral potent allosteric Akt inhibitor, in combination with chemotherapeutic agents in human gastric cancer cell lines. "
10/01/2013 - "We evaluated effects of MK-2206 on cell growth and cell signaling using a panel of gastric cancer cell lines AGS, SNU-1 and SNU 16. "
01/01/2014 - "In conclusion, these results suggested that the synergistic anti-gastric cancer cells ability by RAD001 and MK-2206 involves ERK-dependent autophagic cell death pathway. "
01/01/2014 - "The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway."
10/01/2013 - "MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines."
|4.||Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
12/09/2013 - "Conversely, pharmacologic inhibition of AKT with MK2206 effectively restores glucocorticoid-induced NR3C1 translocation to the nucleus, increases the response of T-ALL cells to glucocorticoid therapy, and effectively reverses glucocorticoid resistance in vitro and in vivo."
11/01/2012 - "MK-2206 decreased T-ALL cell line viability by blocking leukemic cells in the G(0)/G(1) phase of the cell cycle and inducing apoptosis. "
11/01/2012 - "To explore whether Akt could represent a target for therapeutic intervention in T-ALL, we evaluated the effects of the novel allosteric Akt inhibitor, MK-2206, on a panel of human T-ALL cell lines and primary cells from T-ALL patients. "
11/01/2012 - "MK-2206 was cytotoxic to primary T-ALL cells and induced apoptosis in a T-ALL patient cell subset (CD34(+)/CD4(-)/CD7(-)), which is enriched in leukemia-initiating cells. "
03/30/2015 - "This pathway is currently under clinical trials with small molecules inhibitors (SMI).To verify whether a multi-inhibition treatment against Akt protein could enhance the efficacy of individual drug administration and overcome drug resistance as well as to obtain a decrease in single drug concentration, we tested on T-ALL cell lines the effects of combined treatments with three Akt inhibitors with different mode of action, GSK690693, MK-2206 and Perifosine.In"
|5.||Prostatic Neoplasms (Prostate Cancer)
07/19/2013 - "Using a combinatorial kinase inhibitor screening strategy, we discovered that the allosteric Akt inhibitor, MK2206, is able to potentiate BMX inhibitor's antiproliferation efficacy against prostate cancer cells."
09/01/2012 - "In human prostate cancer cell lines, although not in the mouse model, the synergistic actions of MK-2206 and ridaforolimus (MK-8669) are due in part to limiting the mTORC2 feedback activation of Akt. "
11/15/2014 - "The QOD MTD of MK-2206 was also assessed in patients with ovarian and castration-resistant prostate cancers and patients with advanced cancers undergoing multiparametric functional magnetic resonance imaging (MRI) studies, including dynamic contrast-enhanced MRI, diffusion-weighted imaging, magnetic resonance spectroscopy, and intrinsic susceptibility-weighted MRI. "
|6.||D 21266 (perifosine)
|10.||Small Interfering RNA (siRNA)
|2.||Heterologous Transplantation (Xenotransplantation)